LAS VEGAS, NV, Dec. 08, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Digipath, Inc. (OTCQB: DIGP) (“DIGP” or the “Company”),…
NCI Activated as Clinical Site for Phase 1b/2 Clinical Trial to Evaluate HCW9218 in Advanced Pancreatic CancerMIRAMAR, Fla., Dec. 08, 2022…
- INNATE trial Phase 1 dose escalation data showed JTX-8064 was well-tolerated as a single agent and in combination with…
Data presented at San Antonio Breast Cancer Symposium® demonstrate preliminary 4-month PFS rate of 44% in ongoing Phase 2 trial…
LANGHORNE, Pa., Dec. 08, 2022 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (NASDAQ: NXGL, NXGLW), (“NEXGEL” or the “Company”), a leading provider…
Analysis from FORTITUDE-ALS Shows Predicted Survival Risk Score Strongly Correlated with Decline in ALSFRS-R Findings Suggest Inclusion Criteria for COURAGE-ALS Will…
Additional US$5 million in Subscriptions to Close at a Later DateBOCA RATON, Fla., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Jushi…
- Closes Boston research site, reducing workforce by approximately 40 percent to decrease operating expenses -- Continued focus on development…
SCOTTSDALE, Ariz., Dec. 08, 2022 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ: JYNT), a national operator, manager and franchisor of…
Pace of Jurisdictional Allowances Parallels Pre-Clinical and Regulatory ProgressHINGHAM, Mass., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq:…